Our Team
Our team is composed of passionate and highly qualified individuals with combined expertise in chemical engineering, biochemistry, cellular biology, clinical development, business and finance.
- Team
- Senior Management
- Board of Directors
.jpg)
.jpg)
.webp)
.png)
.png)
David J. Mazzo, PhD
Chairman
Elisabeth Sandoval Little, MBA
Board Member
Ms. Little currently serves as a consultant to the pharmaceutical and medical device industries. She has been a member of the board of directors of PROCEPT BioRobotics (NASDAQ: PRCT) since October 2021, where she serves as Chair of the Compensation Committee and member of the Nominating & Governance/ESG Committee. She has also been a member of the board of directors of VYNE Therapeutics, Inc. (NASDAQ: VYNE) since March 2019, where she serves as Chair of the Compensation Committee and member of the Audit Committee.
She previously served on the boards of Satsuma Pharmaceuticals, Inc. (until its acquisition by Shin Nippon Biomedical Laboratories in June 2023), Intersect ENT, Inc. (until its acquisition by Medtronic plc in May 2022), ALASTIN Skincare (until its acquisition by Galderma in January 2022).
Ms. Little previously served as Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals from August 2016 until March 2019 and as Chief Commercial Officer for Kythera Biopharmaceuticals from March 2012 until October 2015, leading the commercial organization through its IPO and $2.1 billion acquisition by Allergan. Earlier, she spent over 20 years at Allergan in commercial leadership roles of increasing responsibility, most recently as Global Vice President, Strategic Marketing.
Ms. Little holds a B.S. in Biology from the University of California, Irvine, and an MBA from Pepperdine University.
.png)
Eric Carter, PhD, M.D.
BOARD MEMBER
Nathalie Chauret, MSc
Board Member
Nathalie Chauret is a consultant specializing in early-stage development for biotechnology companies. She brings over 30 years of experience in drug discovery and development within the biopharmaceutical industry, spanning from discovery research through early clinical phases.
Prior to establishing her consulting practice, Ms. Chauret served as Vice President of Early Phase Development at Bellus Health Inc., where she directed preclinical toxicology and clinical pharmacology programs supporting the advancement of novel therapeutics. Earlier in her career, she held positions of increasing responsibility in DMPK, pharmaceutical sciences, and Phase 1 clinical research at Merck Frosst, ViroChem Pharma, and Vertex Pharmaceuticals.
Ms. Chauret has contributed to the discovery and development of several marketed drugs across therapeutic areas including asthma, pain, osteoporosis, and cystic fibrosis. She holds a Master’s degree in Chemistry from the Université de Montréal and is the author or co-author of more than 50 scientific publications, abstracts, and patents.
.png)
Jamie Stiff, MBA
Board Member
Mr. Stiff joined Genesys Capital in 2002 and became Partner at the firm in 2007. During his career at Genesys, he has been responsible for investments in several early-stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include Enspire DBS Therapy, Feldan Therapeutics, Giiant Pharma Inc., and Veralox Therapeutics Inc. Past board affiliations include Allostera Pharma, EBT Medical, Fairhaven Pharmaceuticals (acquired by Liminal BioSciences Inc., NASDAQ: LMNL), gIcare Pharma, Inversago Pharma (acquired by Novo Nordisk), Interface Biologics, Matregen, Naurex (acquired by Allergan, NYSE: AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Mr. Stiff also volunteers as a board member for BIOTECanada, and as an advisor to the Ontario Genomics Institute (OGI), the Centre for Commercialization of Regenerative Medicine (CCRM) and Medicine by Design, and as an associate with the Creative Destruction Lab (CDL).
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.
Paul Truex, MBA
Board Member
François-Thomas Michaud, PhD, Eng
Board Member & Chief Executive Officer
